Edwards Lifesciences ROA 2010-2025 | EW
Current and historical return on assets (ROA) values for Edwards Lifesciences (EW) over the last 10 years. Return on assets can be defined as an indicator of how profitable a company is relative to its total assets. Calculated by dividing a company's operating earnings by its total assets.
| Edwards Lifesciences ROA - Return on Assets Historical Data |
| Date |
TTM Net Income |
Total Assets |
Return on Assets |
| 2025-03-31 |
$4.18B |
$0.00B |
46.29% |
| 2024-12-31 |
$4.18B |
$13.06B |
36.41% |
| 2024-09-30 |
$4.16B |
$12.97B |
39.45% |
| 2024-06-30 |
$1.47B |
$10.10B |
15.28% |
| 2024-03-31 |
$1.41B |
$9.74B |
15.09% |
| 2023-12-31 |
$1.40B |
$9.36B |
15.42% |
| 2023-09-30 |
$1.43B |
$9.37B |
16.21% |
| 2023-06-30 |
$1.39B |
$9.00B |
16.08% |
| 2023-03-31 |
$1.49B |
$8.65B |
17.51% |
| 2022-12-31 |
$1.52B |
$8.29B |
18.02% |
| 2022-09-30 |
$1.46B |
$8.64B |
17.17% |
| 2022-06-30 |
$1.46B |
$8.43B |
17.37% |
| 2022-03-31 |
$1.54B |
$8.42B |
18.80% |
| 2021-12-31 |
$1.50B |
$8.50B |
19.06% |
| 2021-09-30 |
$1.48B |
$8.16B |
19.53% |
| 2021-06-30 |
$1.46B |
$7.66B |
20.24% |
| 2021-03-31 |
$0.85B |
$7.21B |
12.30% |
| 2020-12-31 |
$0.82B |
$7.24B |
12.42% |
| 2020-09-30 |
$0.79B |
$6.80B |
12.32% |
| 2020-06-30 |
$0.74B |
$6.42B |
11.93% |
| 2020-03-31 |
$1.11B |
$6.08B |
18.39% |
| 2019-12-31 |
$1.05B |
$6.49B |
17.82% |
| 2019-09-30 |
$0.77B |
$5.97B |
13.86% |
| 2019-06-30 |
$0.73B |
$5.57B |
12.99% |
| 2019-03-31 |
$0.77B |
$5.47B |
13.66% |
| 2018-12-31 |
$0.72B |
$5.32B |
12.69% |
| 2018-09-30 |
$0.71B |
$5.96B |
12.33% |
| 2018-06-30 |
$0.66B |
$5.69B |
11.59% |
| 2018-03-31 |
$0.56B |
$5.83B |
10.13% |
| 2017-12-31 |
$0.58B |
$5.67B |
11.07% |
| 2017-09-30 |
$0.75B |
$5.49B |
14.96% |
| 2017-06-30 |
$0.72B |
$5.14B |
15.26% |
| 2017-03-31 |
$0.66B |
$4.78B |
14.86% |
| 2016-12-31 |
$0.57B |
$4.51B |
13.61% |
| 2016-09-30 |
$0.55B |
$4.34B |
13.55% |
| 2016-06-30 |
$0.53B |
$4.05B |
13.36% |
| 2016-03-31 |
$0.52B |
$3.85B |
13.38% |
| 2015-12-31 |
$0.50B |
$4.06B |
13.17% |
| 2015-09-30 |
$0.46B |
$3.88B |
12.78% |
| 2015-06-30 |
$0.44B |
$3.61B |
12.60% |
| 2015-03-31 |
$0.87B |
$3.49B |
25.54% |
| 2014-12-31 |
$0.81B |
$3.52B |
25.24% |
| 2014-09-30 |
$0.78B |
$3.35B |
25.82% |
| 2014-06-30 |
$0.76B |
$3.33B |
27.06% |
| 2014-03-31 |
$0.31B |
$2.65B |
11.92% |
| 2013-12-31 |
$0.39B |
$2.71B |
15.75% |
| 2013-09-30 |
$0.40B |
$2.53B |
17.17% |
| 2013-06-30 |
$0.40B |
$2.34B |
17.45% |
| 2013-03-31 |
$0.37B |
$2.30B |
16.84% |
| 2012-12-31 |
$0.29B |
$2.22B |
13.70% |
| 2012-09-30 |
$0.27B |
$2.20B |
12.84% |
| 2012-06-30 |
$0.25B |
$2.08B |
12.33% |
| 2012-03-31 |
$0.24B |
$2.00B |
11.94% |
| 2011-12-31 |
$0.24B |
$1.98B |
12.00% |
| 2011-09-30 |
$0.24B |
$1.98B |
12.44% |
| 2011-06-30 |
$0.24B |
$2.00B |
12.66% |
| 2011-03-31 |
$0.24B |
$1.93B |
13.31% |
| 2010-12-31 |
$0.22B |
$1.77B |
13.00% |
| 2010-09-30 |
$0.20B |
$1.73B |
12.27% |
| 2010-06-30 |
$0.23B |
$1.64B |
14.11% |
| 2010-03-31 |
$0.22B |
$1.60B |
13.87% |
| 2009-12-31 |
$0.23B |
$1.62B |
15.29% |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
MED INSTRUMENTS |
$44.196B |
$5.440B |
|
Edwards Lifesciences Corporation deals in products and technologies aimed at treating advanced cardiovascular diseases, especially structural heart disease in critically ill patients. The company is the world's leading manufacturer of tissue heart valves and repair products used to replace or repair a patient's diseased or defective heart valve. Edwards is also a leading player in hemodynamic monitoring systems used to measure a patient's cardiovascular function in the hospital setting. The company's products and technologies are categorized into four main areas: Transcatheter Aortic Valve Replacement (TAVR), Transcatheter Mitral and Tricuspid Therapies (TMTT), Surgical Structural Heart, and Critical Care.
|
